Sight Sciences, Inc. (SGHT)Healthcare | Medical Devices | Menlo Park, United States | NasdaqGS
5.20 USD
-0.14
(-2.607%) ⇩
(July 14, 2026, 9:52 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:57 a.m. EDT
The investment case for Sight Sciences is currently broken by a catastrophic multi-year decline. Despite a recent uptick in share price, the underlying business has lost nearly 90% of its value over the last four years, with revenue growth failing to offset massive losses. The fundamentals are dire: the company is burning cash, posting negative operating margins, and returning negative equity to shareholders. This is compounded by a toxic insider environment where executives and top management are actively selling their holdings to cover taxes, signaling a lack of confidence in the company's future. While the stock trades at a low multiple relative to sales, this is a value trap driven by deteriorating quality rather than a bargain. The options market confirms this pessimism, with traders positioning heavily for further drops and offering almost no protection for upside moves. There is no catalyst visible to reverse this structural deterioration, making this a security to avoid entirely. |
| Model | MAE |
|---|---|
| MSTL_125 ✓ | 0.079104 |
| MSTL_96_125 | 0.080350 |
| AutoARIMA | 0.232918 |
| AutoETS | 0.232921 |
| MSTL_96 | 0.234981 |
| MSTL | 0.238975 |
| AutoTheta | 0.255607 |
Forecast horizon: 60 days | Selected: MSTL_125
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.205 |
| Excess Kurtosis | 0.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 77.474 |
| Revenue per Share | 1.506 |
| Market Cap | 282,931,712 |
| Forward P/E | -7.88 |
| Beta | 2.38 |
| Profit Margins | -46.83% |
| Website | https://www.sightsciences.com |
As of July 11, 2026, 4:57 a.m. EDT: Speculators are overwhelmingly bearish, with massive open interest in deep out-of-the-money puts (strikes at 2.5) and heavy volume in ATM puts, while call activity is negligible and concentrated only at the money. Implied volatility is extremely low for puts, suggesting a lack of hedging demand and a consensus expectation of further downside.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.59880245 |
| Address1 | 4,040 Campbell Avenue |
| Address2 | Suite 100 |
| All Time High | 42.57 |
| All Time Low | 1.04 |
| Ask | 6.72 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 185,220 |
| Average Daily Volume3 Month | 242,301 |
| Average Volume | 242,301 |
| Average Volume10Days | 185,220 |
| Beta | 2.378 |
| Bid | 3.78 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 0.998 |
| City | Menlo Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.2 |
| Current Ratio | 5.864 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.4 |
| Day Low | 5.2 |
| Debt To Equity | 77.474 |
| Display Name | Sight Sciences |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -27,012,000 |
| Ebitda Margins | -0.33955002 |
| Enterprise To Ebitda | -9.157 |
| Enterprise To Revenue | 3.109 |
| Enterprise Value | 247,348,096 |
| Eps Current Year | -0.76 |
| Eps Forward | -0.66 |
| Eps Trailing Twelve Months | -0.7 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 352 4401 |
| Fifty Day Average | 5.0028 |
| Fifty Day Average Change | 0.19719982 |
| Fifty Day Average Change Percent | 0.03941789 |
| Fifty Two Week Change Percent | 59.880245 |
| Fifty Two Week High | 9.236 |
| Fifty Two Week High Change | -4.0360003 |
| Fifty Two Week High Change Percent | -0.43698573 |
| Fifty Two Week Low | 3.11 |
| Fifty Two Week Low Change | 2.09 |
| Fifty Two Week Low Change Percent | 0.67202574 |
| Fifty Two Week Range | 3.11 - 9.236 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,355,800,000 |
| Float Shares | 35,116,721 |
| Forward Eps | -0.66 |
| Forward P E | -7.878787 |
| Free Cashflow | -8,579,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 186 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.86169 |
| Gross Profits | 68,550,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.19981001 |
| Held Percent Institutions | 0.53706 |
| Implied Shares Outstanding | 54,409,942 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California. |
| Long Name | Sight Sciences, Inc. |
| Market | us_market |
| Market Cap | 282,931,712 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_141058155 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -37,252,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 290,277,040 |
| Number Of Analyst Opinions | 4 |
| Open | 5.4 |
| Operating Cashflow | -25,118,000 |
| Operating Margins | -0.35603002 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 877 266 1144 |
| Previous Close | 5.34 |
| Price Eps Current Year | -6.842105 |
| Price Hint | 2 |
| Price To Book | 5.2104206 |
| Price To Sales Trailing12 Months | 3.5565186 |
| Profit Margins | -0.46827 |
| Quick Ratio | 5.261 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.83333 |
| Region | US |
| Regular Market Change | -0.14000034 |
| Regular Market Change Percent | -2.6070826 |
| Regular Market Day High | 5.4 |
| Regular Market Day Low | 5.2 |
| Regular Market Day Range | 5.2 - 5.4 |
| Regular Market Open | 5.4 |
| Regular Market Previous Close | 5.34 |
| Regular Market Price | 5.2 |
| Regular Market Time | 1,784,037,134 |
| Regular Market Volume | 4,295 |
| Return On Assets | -0.14335 |
| Return On Equity | -0.56644 |
| Revenue Growth | 0.125 |
| Revenue Per Share | 1.506 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 54,409,942 |
| Shares Percent Shares Out | 0.0134000005 |
| Shares Short | 726,624 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 892,961 |
| Short Name | Sight Sciences, Inc. |
| Short Percent Of Float | 0.0184 |
| Short Ratio | 3.83 |
| Source Interval | 15 |
| State | CA |
| Symbol | SGHT |
| Target High Price | 12.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.75 |
| Target Median Price | 8.5 |
| Total Cash | 84,962,000 |
| Total Cash Per Share | 1.562 |
| Total Debt | 41,761,000 |
| Total Revenue | 79,553,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.41875 |
| Two Hundred Day Average Change | -0.21875 |
| Two Hundred Day Average Change Percent | -0.04036909 |
| Type Disp | Equity |
| Volume | 4,295 |
| Website | https://www.sightsciences.com |
| Zip | 94,025 |